Effects of the therapy with Bifidobacterium animalis subsp. lactis HN019 on experimental periodontitis associated with Metabolic Syndrome. Microtomographic, histomorphometric, immunoenzymatic and gene expression profile study in rats.
In the last few years, there has been a considerable interest in the concept of modulating the intestinal microbiota through the use of specific bacteria in order to improve the host metabolism. Some pre-clinical and clinical studies have demonstrated that the use of probiotics can be a promising therapeutic/preventive alternative to Metabolic Syndrome (MS) and periodontal disease (PD). These conditions are deeply associated and affect millions of people worldwide. Until this moment, there are no studies evaluating the impact of the probiotic therapy on the association MS-PD. The purpose of this study is to evaluate the potential effects of the probiotic agent Bifidobacterium animalis subsp. lactis HN019 on the progression and development of experimental periodontitis associated or not with the co-morbidities of MS in Zucker rats. 32 obese and diabetic male Zucker rats (ZFD - Zucker Lepr-fa/fa) and 32 littermates normoglycemic male Zucker rats (Lean - Zucker-Lepr-+/+) will be used. They will be randomly assigned to groups with ligature-induced PD and control groups (C), with no induction of PD. Each one of this groups will be subdivided into 2 subgroups according to the food protocol, as the following situations: i) Groups ZFD-C and Lean-C (rats without PD - n = 16); ii) Groups ZFD-PROB and Lean-PROB (rats without PD and treated with probiotic - n = 16); iii) Groups ZFD-PD and Lean- PD (rats with PD - n = 16); iv) Groups ZFD-PD-PROB and Lean-PD-PROB (rats with PD and treated with probiotic - n = 16). PD will be induced through the placement of ligatures around the mandibular first molars of each animal for 14 days. The probiotic strain will be daily added to the water of the animals for 8 weeks. All animals will be euthanized 8 weeks after the beginning of the experiment. The following parameters will be evaluated: i) metabolic parameters, expression of adipokines and levels of pro and anti-inflammatory cytokines through immunoenzymatic assays (ELISA and LuminexTM xMAP®) and genic expression analysis (qRT-PCR); ii) levels of alveolar bone and attachment losses through histomorphometric analysis; and iii) bone area, mineral density and volume (micro-CT). Data will be statistically analyzed (p < 0.05). (AU)
Articles published in Agência FAPESP Newsletter about the research grant: